Publications

BibTex format

@article{Nguyen:2020:10.12688/wellcomeopenres.15408.2,
author = {Nguyen, HA and Cooke, GS and Day, JN and Flower, B and Phuong, LT and Hung, TM and Dung, NT and Khoa, DB and Hung, LM and Kestelyn, E and Thwaites, GE and Chau, NVV and Turner, HC},
doi = {10.12688/wellcomeopenres.15408.2},
journal = {Wellcome Open Research},
pages = {129--129},
title = {The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam},
url = {http://dx.doi.org/10.12688/wellcomeopenres.15408.2},
volume = {4},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <ns4:p><ns4:bold>Background:</ns4:bold> Injectable interferon-based therapies have been used to treat hepatitis C virus (HCV) infection since 1991. International guidelines have now moved away from interferon-based therapy towards direct-acting antiviral (DAA) tablet regimens, because of their superior efficacy, excellent side-effect profiles, and ease of administration. Initially DAA drugs were prohibitively expensive for most healthcare systems. Access is now improving through the procurement of low-cost, generic DAAs acquired through voluntary licenses. However, HCV treatment costs vary widely, and many countries are struggling with DAA treatment scale-up. This is not helped by the limited cost data and economic evaluations from low- and middle-income countries to support HCV policy decisions. We conducted a detailed analysis of the costs of treating chronic HCV infection with interferon-based therapy in Vietnam. Understanding these costs is important for performing necessary economic evaluations of novel treatment strategies.</ns4:p><ns4:p> <ns4:bold>Methods:</ns4:bold> We conducted an analysis of the direct medical costs of treating HCV infection with interferon alpha (IFN) and pegylated-interferon alpha (Peg-IFN), in combination with ribavirin, from the health sector perspective at the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, in 2017.</ns4:p><ns4:p> <ns4:bold>Results:</ns4:bold> The total cost of the IFN treatment regimen was estimated to range between US$1,120 and US$1,962. The total cost of the Peg-IFN treatment regimen was between US$2,156 and US$5,887. Drug expenses were the biggest contributor to the total treatment cost (54-89%) and were much higher for the Peg-IFN regimen.</ns4:p><ns4:p> <ns4:bold>Conclusions:</ns4:bold> We found that treating HCV with IFN or Peg-IFN resulted in significant direct medical costs. Of concern, we found that all patie
AU  - Nguyen,HA
AU  - Cooke,GS
AU  - Day,JN
AU  - Flower,B
AU  - Phuong,LT
AU  - Hung,TM
AU  - Dung,NT
AU  - Khoa,DB
AU  - Hung,LM
AU  - Kestelyn,E
AU  - Thwaites,GE
AU  - Chau,NVV
AU  - Turner,HC
DO  - 10.12688/wellcomeopenres.15408.2
EP  - 129
PY  - 2020///
SP  - 129
TI  - The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam
T2  - Wellcome Open Research
UR  - http://dx.doi.org/10.12688/wellcomeopenres.15408.2
VL  - 4
ER  -

Download

ProfessorTimothyHallett

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)